SEC Form 4 · accession 0001209191-16-155965
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kamil Ali-Jackson
Officer — Chief Legal Officer
Period of report
Dec 15, 2016
Accepted (ET)
Dec 19, 2016 · 5:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $28.92 | Dec 15, 2016 | A | 83,200 | A | — | Dec 14, 2026 | Common Stock | 83,200 | 83,200 | D |
| Restricted stock unitsF2,F3 | — | Dec 15, 2016 | A | 13,866 | A | — | — | Common Stock | 13,866 | 13,866 | D |
Explanation of responses
- F1The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant.
- F2Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- F3Subject to the reporting person's continuous service with the issuer as of the applicable vesting date, 50% of the shares underlying these restricted stock units will vest in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone.